Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

Marcos J. Guerrero-Muñoz; Diana L. Castillo-Carranza; Rakez Kayed

doi:10.1016/j.bcp.2013.12.023

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

Marcos J. Guerrero-Muñoz, Diana L. Castillo-Carranza, Rakez Kayed

Research output: Contribution to journal › Review article › peer-review

94 Scopus citations

Abstract

Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.

Original language	English (US)
Pages (from-to)	468-478
Number of pages	11
Journal	Biochemical Pharmacology
Volume	88
Issue number	4
DOIs	https://doi.org/10.1016/j.bcp.2013.12.023
State	Published - Apr 15 2014

Keywords

Amyloid oligomers
Anti-amyloid small molecules
Immunotherapy

ASJC Scopus subject areas

Biochemistry
Pharmacology

Access to Document

10.1016/j.bcp.2013.12.023

Cite this

@article{ca59fc9b6638419d88bad06d25245e9c,

title = "Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins",

abstract = "Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.",

keywords = "Amyloid oligomers, Anti-amyloid small molecules, Immunotherapy",

author = "Guerrero-Mu{\~n}oz, {Marcos J.} and Castillo-Carranza, {Diana L.} and Rakez Kayed",

year = "2014",

month = apr,

day = "15",

doi = "10.1016/j.bcp.2013.12.023",

language = "English (US)",

volume = "88",

pages = "468--478",

journal = "Biochemical Pharmacology",

issn = "0006-2952",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

AU - Guerrero-Muñoz, Marcos J.

AU - Castillo-Carranza, Diana L.

AU - Kayed, Rakez

PY - 2014/4/15

Y1 - 2014/4/15

N2 - Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.

AB - Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.

KW - Amyloid oligomers

KW - Anti-amyloid small molecules

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84897954120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897954120&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2013.12.023

DO - 10.1016/j.bcp.2013.12.023

M3 - Review article

C2 - 24406245

AN - SCOPUS:84897954120

SN - 0006-2952

VL - 88

SP - 468

EP - 478

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

IS - 4

ER -

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this